Member Info for Bella6532

Below is what happened at Levicept after their fundraise... founder dumped in favour of Eliot Forster...did the European fund have anything to do with AS being dumped. If Eliot bought the European fund to the table and they dictated price with much more funding to follow based on trial results, CEO upgrade, a place on the Board.

December 2023

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator, LEVI-04

November 2023

Levicept Appoints Eliot Forster as CEO

October 2022

First patient dosed in multicentre Phase II study of LEVI-04 in osteoarthritis patients. Multiple arm, multi-centre, placebo-controlled study to evaluate five monthly infusions of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. ClinicalTrials.gov ID: NCT05618782

April 2022

Case Study interview with Simon Westbrook, CEO of Levicept in Bioprocess Online discussing his experience in selecting and working with a global CDMO partner, and the value Lonza brought to his virtual company.

https://www.bioprocessonline.com/doc/illustrating-a-successful-small-biotech-cdmo-relationship-0002

September 2021

Closing of £35m Series B financing. All existing investors – Medicxi, Advent Life Sciences and Gilde Healthcare – participate, joined by Pfizer Ventures. Funds to support further development of LEVI-04 including Phase II study.

March 2021

Phase I clinical trial of LEVI-04 successfully completed. Study in osteoarthritis patients confirmed favourable safety, tolerability and pharmacokinetic profile. Analysis of biomarkers indicated target engagement and provided early supporting evidence of efficacy / proof-of-concept. ClinicalTrials.gov ID: NCT03227796

“If the strategy is changing, the board should

be changed. If the board is functioning

properly, it should recognise that new skills

should be brought on to accommodate this.”

And AS should have known this as CEO and not been surprised.

Https://www.criticaleye.com/inspiring/insights-servfile.cfm?id=2239

Does CC's location have any bearing on what is to come???

There is only Active or Resigned.

Beinthelead...don't ask me hun...my questions have already been answered and I've said what I think might be coming down the line.

This is what CC said in the opening part of the Investor Meet Q&A session in answer to the recent fundraise/Diagnotiscs questions submitted.

The 4 key strategic priorities for the short term as laid out by CC.

1. Therapeutics Pipeline/Disease Specific Data

‘Really excited by the sheer number of ways PreCision can be implemented in the next programme.

Simon Bennett quite busy. Commercial deals are really unlocked by this clinical data and so there are MULTIPLE conversations on going.

Progress being made on multiple fronts in the pipeline.

2. Financing

A number of questions to address here and they will address them.

The Board is working on plans to fund all of the areas mentioned above and working on it being a short bit of time to come back to you.

3. Planning Around Diagnostics

Looking to maximise value for shareholders, customers and staff alike and are working on a plan and look forward to communicating this to you in the not too distant future.

4. Evolution of the Board

Critical competencies needed to take Avacta into its next chapter and this is/has been on going in parallel with the CEO search.

Nanomat...I'm not defending him. But for him to take on another position with another company in the same building right around the time CC came on board tells me that AS and the board knew all along that he would be stepping down at some point. As far as many of the decisions made they were not made in isolation he eould have consulted with the Board. Do I think all the decisions were good ones...well I can't really say for sure but they will have been made with more facts than we had at the time. The Pandemic was terrible for most S&M size businesses. The LFT was a great idea but so many British companies got shafted by the Govt and Govt Dept decisions. Many PIs jumped on the Avacta covid bandwagon without even knowing or researching what Avacta was really all about.

All CEOs make duff decisions at some point...nobody is perfect...but one hopes that with an experienced/knowledgable BODs the bad decisions are kept to the minimum.

For a company the size of Avacta...FD/Sec is a one man job....and yes I still only refer to men and women...the rest is BS...

For non believers...

https://www.linkedin.com/posts/sparta-biodiscovery_spinout-sparta-biodiscovery-speeds-commercial-activity-7113497031712624640-ldFK

AS's moving on has been in progress since 2022.

March 2022 CC was appointed to Avacta Board.

April 2022 AS was appointed to the Board of Sparta Biodiscovery

This was not done suddenly...there has been a 2 year transition period so stop making out it's new and it was all done because of shareholders wanting it to happen bla bla bla...get over it...it's done...it was planned...

End of...

AS has been with Sparta Biodiscovery for some time so I guess he's now there on a full time basis...no need to keep walking between companies now...

https://suite.endole.co.uk/insight/company/13952962-sparta-biodiscovery-limited

'Doxorubicin not suitable for some mid FAP pateints' whoever wrote and put up this subject heading doesn't have a clue.

about what AVA6000 is or does....geez

No I don't think it's going to be plural...just the addition of someone new 😉

Don't forget Monday is a holiday...

And that's what we were told wasn't it. There are two distinct parts...Precision and the Drug it carries.

1. PreCision targets high and mid FAP almost without any difference....great news for PreCision.

2. The drug - in AVA6000's case Dox...FAP levels are not the key here it's the effect Dox has on certain cancers.

Some cancers react better to Dox than others.

Dox levels in the cancer environment remeained higher than in the blood even with increased dosing.

Dose levels and time intervals between doses matter and 2W data should help prove this.

Peanuts snd a distraction...they employ teenagers who don't research...they just look at chart trends...silly billies...

'The 1,000,000 on 26 April, which I am assuming you have picked up from Companies House was the issue of shares under the Block Listing, so does not need its own RNS.'

Thanks LLP...

Had a reply and as I said the shareholder is responsible for informing the company as thresholds crossed and the company then RNSs the TR1. For some types of funds, however, they don't have to report until 5% crossed which is the case for the one on the website.

Now the shareholder list doesn't really look fully up to date but even if it is there is nobody listed that fits the bill really for the European chappies and certainly not by percentage change if they are significant...which I tend to think they are...and the new Board addition may well be linked to the European fund hence no name mentioned and won't be until Board member announced.

One other thing I can say... it's been confirmed they are not the same company as the one now shown on the website...

Can someone please remind me how we know AXA Farmington Biotech fund took part in the placing.